Search

Your search keyword '"Galldiks, Norbert"' showing total 1,407 results
Start Over Author "Galldiks, Norbert"
1,407 results on '"Galldiks, Norbert"'

1. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.

Author

Wang, Justin, Landry, Alexander, Raleigh, David, Sahm, Felix, Walsh, Kyle, Goldbrunner, Roland, Yefet, Leeor, Tonn, Jörg, Gui, Chloe, Ostrom, Quinn, Barnholtz-Sloan, Jill, Perry, Arie, Ellenbogen, Yosef, Hanemann, C, Jungwirth, Gerhard, Jenkinson, Michael, Tabatabai, Ghazaleh, Mathiesen, Tiit, McDermott, Mike, Tatagiba, Marcos, la Fougère, Christian, Maas, Sybren, Galldiks, Norbert, Albert, Nathalie, Brastianos, Priscilla, Ehret, Felix, Minniti, Giuseppe, Lamszus, Katrin, Ricklefs, Franz, Schittenhelm, Jens, Drummond, Katharine, Dunn, Ian, Pathmanaban, Omar, Cohen-Gadol, Aaron, Sulman, Erik, Tabouret, Emeline, Le Rhun, Emelie, Mawrin, Christian, Moliterno, Jennifer, Weller, Michael, Bi, Wenya, Gao, Andrew, Yip, Stephen, Niyazi, Maximilian, Aldape, Kenneth, Wen, Patrick, Short, Susan, Preusser, Matthias, Nassiri, Farshad, and Zadeh, Gelareh

Subjects
extra-axial, meningioma, methylation, molecular, neurofibromatosis 2, nonmalignant, radiotherapy, Humans, Meningioma, Meningeal Neoplasms, Consensus, Biomarkers, Tumor
Abstract

Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.

Published
2024

2. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0

Author

Verger, Antoine, Tolboom, Nelleke, Cicone, Francesco, Chang, Susan M., Furtner, Julia, Galldiks, Norbert, Gempt, Jens, Guedj, Eric, Huang, Raymond Y., Johnson, Derek R., Law, Ian, Le Rhun, Emilie, Short, Susan C., Bent, M. J. Van den, Weehaeghe, Donatienne Van, Vogelbaum, Michael A., Wen, Patrick Y., Albert, Nathalie L., and Preusser, Matthias

Published
2025
Full Text
View/download PDF

4. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Author

Albert, Nathalie L., Preusser, Matthias, Traub-Weidinger, Tatjana, Tolboom, Nelleke, Law, Ian, Palmer, Joshua D., Guedj, Eric, Furtner, Julia, Fraioli, Francesco, Huang, Raymond Y., Johnson, Derek R., Deroose, Christophe M., Herrmann, Ken, Vogelbaum, Michael, Chang, Susan, Tonn, Joerg-Christian, Weller, Michael, Wen, Patrick Y., van den Bent, Martin J., Verger, Antoine, Ivanidze, Jana, and Galldiks, Norbert

Published
2024
Full Text
View/download PDF

5. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.

Author

Albert, Nathalie, Galldiks, Norbert, Ellingson, Benjamin, van den Bent, Martin, Chang, Susan, Cicone, Francesco, de Groot, John, Koh, Eng-Siew, Law, Ian, Le Rhun, Emilie, Mair, Maximilian, Minniti, Giuseppe, Rudà, Roberta, Scott, Andrew, Short, Susan, Smits, Marion, Suchorska, Bogdana, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Tonn, Joerg-Christian, Verger, Antoine, Weller, Michael, Wen, Patrick, and Preusser, Matthias

Subjects
Humans, Glioma, Amino Acids, Internal Medicine, Neurology, Positron-Emission Tomography, Transcription Factors
Abstract

Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas.

Published
2024

6. Radiomics workflow definition & challenges - German priority program 2177 consensus statement on clinically applied radiomics

Author

Floca, Ralf, Bohn, Jonas, Haux, Christian, Wiestler, Benedikt, Zöllner, Frank G., Reinke, Annika, Weiß, Jakob, Nolden, Marco, Albert, Steffen, Persigehl, Thorsten, Norajitra, Tobias, Baeßler, Bettina, Dewey, Marc, Braren, Rickmer, Büchert, Martin, Fallenberg, Eva Maria, Galldiks, Norbert, Gerken, Annika, Götz, Michael, Hahn, Horst K., Haubold, Johannes, Haueise, Tobias, Große Hokamp, Nils, Ingrisch, Michael, Iuga, Andra-Iza, Janoschke, Marco, Jung, Matthias, Kiefer, Lena Sophie, Lohmann, Philipp, Machann, Jürgen, Moltz, Jan Hendrik, Nattenmüller, Johanna, Nonnenmacher, Tobias, Oerther, Benedict, Othman, Ahmed E., Peisen, Felix, Schick, Fritz, Umutlu, Lale, Wichtmann, Barbara D., Zhao, Wenzhao, Caspers, Svenja, Schlemmer, Heinz-Peter, Schlett, Christopher L., Maier-Hein, Klaus, and Bamberg, Fabian

Published
2024
Full Text
View/download PDF

7. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups

Author

Karschnia, Philipp, Smits, Marion, Reifenberger, Guido, Le Rhun, Emilie, Ellingson, Benjamin M, Galldiks, Norbert, Kim, Michelle M, Huse, Jason T, Schnell, Oliver, Harter, Patrick N, Mohme, Malte, Panel, Rater, Aldape, Kenneth, Baehring, Joachim M, Bello, Lorenzo, Brat, Daniel J, Cahill, Daniel P, Chung, Caroline, Colman, Howard, Dietrich, Jorg, Drummond, Katharine, Esquenazi, Yoshua, Gerstner, Elizabeth R, Furtner, Julia, Garibotto, Valentina, Kaufmann, Timothy J, Komori, Takashi, Kotecha, Rupesh, Liau, Linda M, Lupo, Janine M, Minniti, Giuseppe, Narita, Yoshitaka, Niyazi, Maximilian, Perry, Arie, Preusser, Matthias, Rudà, Roberta, Sanai, Nader, Schmidt, Nils-Ole, Steinbach, Joachim P, Thust, Stefanie C, Tolboom, Nelleke, van der Hoorn, Anouk, van der Vaart, Thijs, Verger, Antoine, Vik-Mo, Einar Osland, Watts, Colin, Westphal, Manfred, Wesseling, Pieter, Young, Jacob S, von Baumgarten, Louisa, Albert, Nathalie L, Huang, Raymond Y, Mehta, Minesh P, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael A, Chang, Susan M, Berger, Mitchel S, and Tonn, Joerg-Christian

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Brain Cancer, Brain Disorders, Rare Diseases, Neurosciences, Humans, Brain Neoplasms, Prospective Studies, Biological Specimen Banks, Neoplasm Recurrence, Local, Glioma, Expert Rater Panel, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Surgical resection represents the standard of care for people with newly diagnosed diffuse gliomas, and the neuropathological and molecular profile of the resected tissue guides clinical management and forms the basis for research. The Response Assessment in Neuro-Oncology (RANO) consortium is an international, multidisciplinary effort that aims to standardise research practice in neuro-oncology. These recommendations represent a multidisciplinary consensus from the four RANO groups: RANO resect, RANO recurrent glioblastoma, RANO radiotherapy, and RANO/PET for a standardised workflow to achieve a representative tumour evaluation in a disease characterised by intratumoural heterogeneity, including recommendations on which tumour regions should be surgically sampled, how to define those regions on the basis of preoperative imaging, and the optimal sample volume. Practical recommendations for tissue sampling are given for people with low-grade and high-grade gliomas, as well as for people with newly diagnosed and recurrent disease. Sampling of liquid biopsies is also addressed. A standardised workflow for subsequent handling of the resected tissue is proposed to avoid information loss due to decreasing tissue quality or insufficient clinical information. The recommendations offer a framework for prospective biobanking studies.

Published
2023

8. Advances in PET imaging for meningioma patients.

Author

Galldiks, Norbert, Albert, Nathalie L, Wollring, Michael, Werner, Jan-Michael, Lohmann, Philipp, Villanueva-Meyer, Javier E, Fink, Gereon R, Langen, Karl-Josef, and Tonn, Joerg-Christian

Subjects
DOTATATE, FDG, FLT, SiTATE, amino acid PET, somatostatin receptor-expression, Brain Cancer, Brain Disorders, Biomedical Imaging, Cancer, Rare Diseases, Neurosciences, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies
Abstract

In patients with meningioma, diagnosis and treatment planning are predominantly based on anatomical imaging using MRI or CT. Constraints of these imaging modalities include precise meningioma delineation-especially at the skull base, in the case of trans-osseus growth, and in tumors with complex geometry-and the differentiation of post-therapeutic reactive changes from meningioma relapse. Advanced metabolic imaging using PET may help to characterize specific metabolic and cellular features providing additional information beyond the information derived from anatomical imaging alone. Accordingly, the use of PET in meningioma patients is steadily increasing. This review summarizes recent advances in PET imaging helpful for improving the clinical management of patients with meningioma.

Published
2023

10. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study

Author

Vollmuth, Philipp, Foltyn, Martha, Huang, Raymond Y, Galldiks, Norbert, Petersen, Jens, Isensee, Fabian, van den Bent, Martin J, Barkhof, Frederik, Park, Ji Eun, Park, Yae Won, Ahn, Sung Soo, Brugnara, Gianluca, Meredig, Hagen, Jain, Rajan, Smits, Marion, Pope, Whitney B, Maier-Hein, Klaus, Weller, Michael, Wen, Patrick Y, Wick, Wolfgang, and Bendszus, Martin

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Rare Diseases, Cancer, Brain Disorders, Neurosciences, Brain Cancer, Bioengineering, Machine Learning and Artificial Intelligence, Orphan Drug, Humans, Glioblastoma, Brain Neoplasms, Artificial Intelligence, Reproducibility of Results, Glioma, Artificial intelligence (AI)-based decision support, RANO, tumor response assessment, tumor volumetry, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundTo assess whether artificial intelligence (AI)-based decision support allows more reproducible and standardized assessment of treatment response on MRI in neuro-oncology as compared to manual 2-dimensional measurements of tumor burden using the Response Assessment in Neuro-Oncology (RANO) criteria.MethodsA series of 30 patients (15 lower-grade gliomas, 15 glioblastoma) with availability of consecutive MRI scans was selected. The time to progression (TTP) on MRI was separately evaluated for each patient by 15 investigators over two rounds. In the first round the TTP was evaluated based on the RANO criteria, whereas in the second round the TTP was evaluated by incorporating additional information from AI-enhanced MRI sequences depicting the longitudinal changes in tumor volumes. The agreement of the TTP measurements between investigators was evaluated using concordance correlation coefficients (CCC) with confidence intervals (CI) and P-values obtained using bootstrap resampling.ResultsThe CCC of TTP-measurements between investigators was 0.77 (95% CI = 0.69,0.88) with RANO alone and increased to 0.91 (95% CI = 0.82,0.95) with AI-based decision support (P = .005). This effect was significantly greater (P = .008) for patients with lower-grade gliomas (CCC = 0.70 [95% CI = 0.56,0.85] without vs. 0.90 [95% CI = 0.76,0.95] with AI-based decision support) as compared to glioblastoma (CCC = 0.83 [95% CI = 0.75,0.92] without vs. 0.86 [95% CI = 0.78,0.93] with AI-based decision support). Investigators with less years of experience judged the AI-based decision as more helpful (P = .02).ConclusionsAI-based decision support has the potential to yield more reproducible and standardized assessment of treatment response in neuro-oncology as compared to manual 2-dimensional measurements of tumor burden, particularly in patients with lower-grade gliomas. A fully-functional version of this AI-based processing pipeline is provided as open-source (https://github.com/NeuroAI-HD/HD-GLIO-XNAT).

Published
2023

12. Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.

Author

Galldiks, Norbert, Langen, Karl-Josef, Albert, Nathalie L, Law, Ian, Kim, Michelle M, Villanueva-Meyer, Javier E, Soffietti, Riccardo, Wen, Patrick Y, Weller, Michael, and Tonn, Joerg C

Subjects
Cancer, Neurosciences, Rare Diseases, Brain Disorders, Brain Cancer, Bioengineering, Biomedical Imaging, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Neurological, Humans, Radiopharmaceuticals, Positron-Emission Tomography, Brain Neoplasms, fluciclovine, Immuno-PET, PSMA, somatostatin, TSPO, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Many studies in patients with brain tumors evaluating innovative PET tracers have been published in recent years, and the initial results are promising. Here, the Response Assessment in Neuro-Oncology (RANO) PET working group provides an overview of the literature on novel investigational PET tracers for brain tumor patients. Furthermore, newer indications of more established PET tracers for the evaluation of glucose metabolism, amino acid transport, hypoxia, cell proliferation, and others are also discussed. Based on the preliminary findings, these novel investigational PET tracers should be further evaluated considering their promising potential. In particular, novel PET probes for imaging of translocator protein and somatostatin receptor overexpression as well as for immune system reactions appear to be of additional clinical value for tumor delineation and therapy monitoring. Progress in developing these radiotracers may contribute to improving brain tumor diagnostics and advancing clinical translational research.

Published
2022

13. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements

Author

Villanueva-Meyer, Javier E, Bakas, Spyridon, Tiwari, Pallavi, Lupo, Janine M, Calabrese, Evan, Davatzikos, Christos, Bi, Wenya Linda, Ismail, Marwa, Akbari, Hamed, Lohmann, Philipp, Booth, Thomas C, Wiestler, Benedikt, Aerts, Hugo J W L, Rasool, Ghulam, Tonn, Joerg C, Nowosielski, Martha, Jain, Rajan, Colen, Rivka R, Pati, Sarthak, Baid, Ujjwal, Vollmuth, Philipp, Macdonald, David, Vogelbaum, Michael A, Chang, Susan M, Huang, Raymond Y, and Galldiks, Norbert

Published
2024
Full Text
View/download PDF

14. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice

Author

Bakas, Spyridon, Vollmuth, Philipp, Galldiks, Norbert, Booth, Thomas C, Aerts, Hugo J W L, Bi, Wenya Linda, Wiestler, Benedikt, Tiwari, Pallavi, Pati, Sarthak, Baid, Ujjwal, Calabrese, Evan, Lohmann, Philipp, Nowosielski, Martha, Jain, Rajan, Colen, Rivka, Ismail, Marwa, Rasool, Ghulam, Lupo, Janine M, Akbari, Hamed, Tonn, Joerg C, Macdonald, David, Vogelbaum, Michael, Chang, Susan M, Davatzikos, Christos, Villanueva-Meyer, Javier E, and Huang, Raymond Y

Published
2024
Full Text
View/download PDF

16. Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings

Author

Millward, Christopher P, Armstrong, Terri S, Barrington, Heather, Bell, Sabrina, Brodbelt, Andrew R, Bulbeck, Helen, Crofton, Anna, Dirven, Linda, Georgious, Theo, Grundy, Paul L, Islim, Abdurrahman I, Javadpour, Mohsen, Keshwara, Sumirat M, Koszdin, Shelli D, Marson, Anthony G, McDermott, Michael W, Meling, Torstein R, Oliver, Kathy, Plaha, Puneet, Preusser, Matthias, Santarius, Thomas, Srikandarajah, Nisaharan, Taphoorn, Martin JB, Turner, Carole, Watts, Colin, Weller, Michael, Williamson, Paula R, Zadeh, Gelareh, Najafabadi, Amir H Zamanipoor, Jenkinson, Michael D, Aldape, Kenneth, Au, Karolyn, Barnhartz-Sloan, Jill, Bi, Wenya Linda, Behling, Felix, Brastianos, Priscilla K, Brodie, Chaya, Butowski, Nicholas, Carlotti, Carlos, Castro, Ana, Cohen-Gadol, Aaron, Couce, Marta, Cusimano, Michael D, DiMeco, Francesco, Drummond, Katharine, Dunn, Ian F, Erker, Craig, Felicella, Michelle, Fountain, Daniel M, Galanis, Evanthia, Galldiks, Norbert, Giannini, Caterina, Goldbrunner, Roland, Griffith, Brent, Hashizume, Rintaro, Hanemann, C Oliver, Herold-Mende, Christel, Hnenny, Luke, Horbinski, Craig, Huang, Raymond Y, James, David, Jungk, Christine, Jungwirth, Gerhard, Kaufmann, Timothy J, Krischek, Boris, Kurz, Sylvia, Lachance, Daniel, Lafougère, Christian, Lamszus, Katrin, Lee, Ian, Liu, Jeff C, Makarenko, Serge, Malta, Tathiana, Mamatjan, Yasin, Mansouri, Alireza, Mawrin, Christian, McDermott, Michael, Moliterno-Gunel, Jennifer, Morokoff, Andrew, Munoz, David, Nassiri, Farshad, Noushmehr, Houtan, Ng, Ho-Keung, Perry, Arie, Pirouzmand, Farhad, Poisson, Laila M, Pollo, Bianca, Ragunathan, Aditya, Raleigh, David, Renovanz, Mirjam, Ricklefs, Franz, Sahm, Felix, Saladino, Andrea, Santacroce, Antonio, Schittenhelm, Jens, and Schichor, Christian

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Neurosciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Consensus, Delphi Technique, Humans, Meningeal Neoplasms, Meningioma, Research Design, Systematic Reviews as Topic, Treatment Outcome, EORTC BTG, ICOM, EANO, SNO, RANO-PRO, BNOS, SBNS, BIMS, TBTC, International Brain Tumour Alliance, Brainstrust, and Brain Tumour Foundation of Canada, clinical trial, core outcome set, meningioma, Public Health and Health Services, Other Medical and Health Sciences, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

IntroductionMeningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two 'Core Outcome Sets' (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.Methods and analysisTwo systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.Ethics and disseminationInstitutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.Trial registration numberCOMET study ID 1508.

Published
2022

17. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Author

Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich, and Schaub, Christina

Published
2023
Full Text
View/download PDF

19. Imaging Characteristics of Meningiomas

Author

Galldiks, Norbert, Hattingen, Elke, Langen, Karl-Josef, Tonn, Jörg C., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Steinlein, Ortrud, Series Editor, Xiao, Junjie, Series Editor, Zadeh, Gelareh, editor, Goldbrunner, Roland, editor, Krischek, Boris, editor, and Nassiri, Farshad, editor

Published
2023
Full Text
View/download PDF

21. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups

Author

Aldape, Kenneth, Baehring, Joachim M., Bello, Lorenzo, Brat, Daniel J., Cahill, Daniel P., Chung, Caroline, Colman, Howard, Dietrich, Jorg, Drummond, Katharine, Esquenazi, Yoshua, Gerstner, Elizabeth R., Furtner, Julia, Garibotto, Valentina, Kaufmann, Timothy J., Komori, Takashi, Kotecha, Rupesh, Liau, Linda M., Lupo, Janine M., Minniti, Giuseppe, Narita, Yoshitaka, Niyazi, Maximilian, Perry, Arie, Preusser, Matthias, Rudà, Roberta, Sanai, Nader, Schmidt, Nils-Ole, Steinbach, Joachim P., Thust, Stefanie C., Tolboom, Nelleke, van der Hoorn, Anouk, van der Vaart, Thijs, Verger, Antoine, Vik-Mo, Einar Osland, Watts, Colin, Westphal, Manfred, Wesseling, Pieter, Young, Jacob S., Karschnia, Philipp, Smits, Marion, Reifenberger, Guido, Le Rhun, Emilie, Ellingson, Benjamin M, Galldiks, Norbert, Kim, Michelle M, Huse, Jason T, Schnell, Oliver, Harter, Patrick N, Mohme, Malte, von Baumgarten, Louisa, Albert, Nathalie L, Huang, Raymond Y, Mehta, Minesh P, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael A, Chang, Susan M, Berger, Mitchel S, and Tonn, Joerg-Christian

Published
2023
Full Text
View/download PDF

26. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression

Author

Galldiks, Norbert, Kocher, Martin, Ceccon, Garry, Werner, Jan-Michael, Brunn, Anna, Deckert, Martina, Pope, Whitney B, Soffietti, Riccardo, Le Rhun, Emilie, Weller, Michael, Tonn, Jörg C, Fink, Gereon R, and Langen, Karl-Josef

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Radiation Oncology, Precision Medicine, Brain Disorders, Cancer, Biomedical Imaging, Brain Cancer, Neurosciences, Immunotherapy, Vaccine Related, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Immunization, 4.2 Evaluation of markers and technologies, Brain Neoplasms, Disease Progression, Humans, Immune Checkpoint Inhibitors, Molecular Targeted Therapy, Neuroimaging, Treatment Outcome, brain metastasis, FET PET, immune checkpoint inhibitors, lung cancer, melanoma, radiomics, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT-either alone (especially ICI) or in combination with radiotherapy-imaging findings on anatomical contrast-enhanced MRI can be unpredictable and highly variable, and are often difficult to interpret regarding treatment response and outcome. This review aims at summarizing the imaging challenges related to TT and ICI monotherapy as well as combined with radiotherapy in patients with brain metastases, and to give an overview on advanced imaging techniques which potentially overcome some of these imaging challenges. Currently, major evidence suggests that imaging parameters especially derived from amino acid PET, perfusion-/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional information for the differentiation of treatment-induced changes from brain metastases recurrence and the evaluation of treatment response.

Published
2020

27. PET imaging in patients with brain metastasis—report of the RANO/PET group

Author

Galldiks, Norbert, Langen, Karl-Josef, Albert, Nathalie L, Chamberlain, Marc, Soffietti, Riccardo, Kim, Michelle M, Law, Ian, Le Rhun, Emilie, Chang, Susan, Schwarting, Julian, Combs, Stephanie E, Preusser, Matthias, Forsyth, Peter, Pope, Whitney, Weller, Michael, and Tonn, Jörg C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Orphan Drug, Neurosciences, Clinical Trials and Supportive Activities, Radiation Oncology, Bioengineering, Rare Diseases, Minority Health, Brain Disorders, Clinical Research, Cancer, Brain Cancer, Health Disparities, 4.1 Discovery and preclinical testing of markers and technologies, Animals, Brain Neoplasms, Humans, Molecular Imaging, Positron-Emission Tomography, Radiopharmaceuticals, amino acid PET, brain metastases, FDG PET, FET, pseudoprogression, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.

Published
2019

31. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Author

Piccardo, Arnoldo, Albert, Nathalie L., Borgwardt, Lise, Fahey, Frederic H., Hargrave, Darren, Galldiks, Norbert, Jehanno, Nina, Kurch, Lars, Law, Ian, Lim, Ruth, Lopci, Egesta, Marner, Lisbeth, Morana, Giovanni, Young Poussaint, Tina, Seghers, Victor J., Shulkin, Barry L., Warren, Katherine E., Traub-Weidinger, Tatjana, and Zucchetta, Pietro

Published
2022
Full Text
View/download PDF

32. Borderline Findings in O -(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice.

Author

Langen, Karl-Josef, Stoffels, Gabriele, Filss, Christian P., Kocher, Martin, Lerche, Christoph, Sabel, Michael, Rapp, Marion, Noltemeier, Hosai, Werner, Jan-Michael, Ceccon, Garry, Wollring, Michael M., Rosen, Jurij, Steinbach, Joachim P., Hattingen, Elke, Weinzierl, Martin R., Stoffel, Michael, Clusmann, Hans, Shah, N. Jon, Mottaghy, Felix M., and Galldiks, Norbert

Published
2025
Full Text
View/download PDF

33. Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.

Author

Zeyen, Thomas, Böhm, Laura, Paech, Daniel, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Schneider-Rothhaar, Javen Lennard, Steinbach, Joachim Peter, Hau, Peter, Kowalski, Thomas, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, and Galldiks, Norbert

Published
2025
Full Text
View/download PDF

34. Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Author

Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich, and Schaub, Christina

Published
2023
Full Text
View/download PDF

44. PET imaging of gliomas: Status quo and quo vadis?

Author

Galldiks, Norbert, Lohmann, Philipp, Friedrich, Michel, Werner, Jan-Michael, Stetter, Isabelle, Wollring, Michael M, Ceccon, Garry, Stegmayr, Carina, Krause, Sandra, Fink, Gereon R, Law, Ian, Langen, Karl-Josef, and Tonn, Joerg-Christian

Published
2024
Full Text
View/download PDF

46. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

Author

Galldiks, Norbert, Law, Ian, Pope, Whitney B, Arbizu, Javier, and Langen, Karl-Josef

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Neurosciences, Brain Disorders, Cancer, Rare Diseases, Brain Cancer, Amino Acids, Brain Neoplasms, Dihydroxyphenylalanine, Humans, Methionine, Positron-Emission Tomography, Radiopharmaceuticals, Tyrosine, PET, FET, MET, FDOPA, Glioma, Temozolomide, Bevacizumab, Immunotherapy, Checkpoint inhibitors, Pseudoprogression, Pseudoresponse, Biological psychology, Clinical and health psychology
Abstract

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers 11C-methyl-l-methionine (MET), O-(2-[18F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.

Published
2017

47. MRI and18F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis

Author

Rosen, Jurij, primary, Werner, Jan-Michael, additional, Ceccon, Garry S., additional, Rosen, Elena K., additional, Wollring, Michael M., additional, Stetter, Isabelle, additional, Lohmann, Philipp, additional, Mottaghy, Felix M., additional, Fink, Gereon R., additional, Langen, Karl-Josef, additional, and Galldiks, Norbert, additional

Published
2024
Full Text
View/download PDF

48. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review

Author

Nayak, Lakshmi, primary, Bettegowda, Chetan, additional, Scherer, Florian, additional, Galldiks, Norbert, additional, Ahluwalia, Manmeet, additional, Baraniskin, Alexander, additional, von Baumgarten, Louisa, additional, Bromberg, Jacoline E C, additional, Ferreri, Andrés J M, additional, Grommes, Christian, additional, Hoang-Xuan, Khê, additional, Kühn, Julia, additional, Rubenstein, James L, additional, Rudà, Roberta, additional, Weller, Michael, additional, Chang, Susan M, additional, van den Bent, Martin J, additional, Wen, Patrick Y, additional, and Soffietti, Riccardo, additional

Published
2024
Full Text
View/download PDF

50. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Author

Albert, Nathalie L, Weller, Michael, Suchorska, Bogdana, Galldiks, Norbert, Soffietti, Riccardo, Kim, Michelle M, la Fougère, Christian, Pope, Whitney, Law, Ian, Arbizu, Javier, Chamberlain, Marc C, Vogelbaum, Michael, Ellingson, Ben M, and Tonn, Joerg C

Subjects
Animals, Humans, Glioma, Brain Neoplasms, Radiopharmaceuticals, Positron-Emission Tomography, Molecular Imaging, PET imaging, amino acid PET, glioma, guideline, recommendations, Rare Diseases, Neurosciences, Brain Cancer, Cancer, Clinical Research, Brain Disorders, Biomedical Imaging, Orphan Drug, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers ((11)C-MET, (18)F-FET, and (18)F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results